Mounjaro and Elevated Liver Enzymes — What It Means for Australian Patients

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes found predominantly inside liver cells. When liver cells are stressed, damaged, or inflamed, these enzymes leak into the bloodstream, producing elevated readings on routine blood tests.

Normal reference ranges vary slightly between Australian laboratories, but generally:

• ALT: up to 35–40 U/L for women, up to 45–55 U/L for men
• AST: up to 35–40 U/L for most adults

Elevations up to three times the upper limit of normal are considered mild. Elevations above three times the upper limit — above approximately 120 U/L for most adults — warrant clinical review and investigation of the cause.

It is important to understand that elevated liver enzymes are a non-specific finding. They can reflect many different conditions — fatty liver disease, alcohol intake, viral hepatitis, muscle breakdown from exercise, thyroid disorders, certain medications, or the metabolic changes that occur during significant weight loss. An elevated enzyme reading alone does not tell you the cause.

Mounjaro (tirzepatide) — a dual GLP-1 and GIP receptor agonist made by Eli Lilly — produces greater average weight loss than any other currently approved weight management medication, with phase 3 trial participants losing an average of 20–21% of body weight over 72 weeks.

This magnitude of weight loss has well-characterised effects on liver enzymes. In most patients with metabolic-driven liver enzyme elevations — particularly those caused by MASLD (fatty liver disease), obesity, or type 2 diabetes — tirzepatide produces significant improvements in ALT and AST over time. As liver fat decreases and insulin sensitivity improves, liver enzyme levels typically fall toward or into the normal range within 6–12 months.

Mounjaro is commonly associated with liver enzyme improvement when elevated ALT and AST are driven by fatty liver disease, obesity, or type 2 diabetes. Benefits are mostly indirect — reduced liver fat and better insulin sensitivity lead to lower enzyme levels.

Phase 2 clinical trials of tirzepatide in patients with MASLD confirmed this pattern: significant reductions in liver fat content and liver enzymes were observed compared to placebo, with the magnitude of improvement correlating with the degree of weight loss achieved.

Despite the overall beneficial trajectory, some patients experience a transient rise in liver enzymes in the early months on Mounjaro — particularly during the period of rapid weight loss.

The mechanism is the same as with other GLP-1 medications: when body fat is mobilised rapidly, the liver receives an increased influx of free fatty acids for processing. During periods of very rapid weight loss — more than 1–1.5kg per week, which is possible in the early dose escalation phase on Mounjaro — this fat mobilisation can temporarily overwhelm the liver's processing capacity, producing a short-term elevation in liver enzymes.

This is not drug-induced liver injury. It is a physiological response to the rate of fat metabolism, and it is the same phenomenon seen with rapid weight loss from any cause — including very low calorie diets and bariatric surgery. The elevation is self-limiting. As weight loss stabilises to a more gradual pace — typically from month 3 onwards on Mounjaro — liver enzyme levels stabilise and then continue to improve.

By February 2026, research into Mounjaro and liver health has become clearer. Overall, evidence suggests that most patients experience liver improvement, not harm. However, monitoring remains essential, especially during the first months of treatment.

Most transient enzyme elevations on Mounjaro are benign and self-resolving. However, the following circumstances warrant clinical review and further investigation:

Persistent elevation beyond 3 months. If ALT or AST remains elevated after the initial rapid weight loss phase, further investigation is needed to exclude other causes — including pre-existing MASLD, viral hepatitis, autoimmune liver disease, alcohol consumption, or other medications.

Elevations above 3 times the upper limit of normal. ALT above approximately 120 U/L, or AST above approximately 120 U/L, at any point requires clinical review.

Symptoms suggesting liver involvement. Jaundice (yellowing of the skin or eyes), dark urine, pale stools, right upper quadrant abdominal pain, or unexplained fatigue occurring after starting Mounjaro should prompt urgent medical review.

Pre-existing liver disease. Patients with known MASLD, hepatitis B or C, autoimmune liver disease, or any history of liver fibrosis should have established baseline liver function before starting Mounjaro and be monitored at regular intervals.

It is worth noting that a rare case of drug-induced liver injury associated with semaglutide (a related GLP-1 medication) was reported in a 2025 case report — highlighting that while clinically significant drug-induced liver injury is very rare with this class of medications, it is not impossible. Significant liver enzyme increases occur in less than 1% of patients during Mounjaro treatment. Persistent unexplained enzyme elevations should always be investigated rather than assumed to be benign.

One of the most clinically important — and frequently missed — explanations for elevated liver enzymes on Mounjaro is pre-existing undiagnosed MASLD.

MASLD affects approximately 30% of Australian adults. The condition is often completely asymptomatic in its early stages. Many Australians starting Mounjaro for weight management have never had their liver function checked and do not know they have fatty liver disease.

When Mounjaro is started and routine blood tests are performed for the first time in years, elevated liver enzymes may be discovered. These enzymes often reflect pre-existing MASLD — disease that was there before Mounjaro was ever started — rather than any adverse effect of the medication.

This distinction is clinically important because it completely changes the management decision. If elevated enzymes reflect pre-existing MASLD, stopping Mounjaro is likely the wrong response — tirzepatide is one of the most effective treatments available for reducing liver fat and improving metabolic liver disease. Continuing therapy while monitoring the response is often the appropriate path, in consultation with a hepatologist or gastroenterologist.

The most effective way to distinguish between these scenarios is a FIB-4 score calculated from baseline blood tests before starting Mounjaro, so any subsequent changes can be interpreted in context.

If you have elevated liver enzymes on Mounjaro, the first clinical step is a FIB-4 score calculation. FIB-4 uses age, ALT, AST, and platelet count — results already available from a standard blood panel — to estimate the probability of significant liver fibrosis.

A FIB-4 below 1.3: low risk of advanced fibrosis. Monitor annually.

A FIB-4 between 1.3 and 2.67: indeterminate — liver elastography recommended.

A FIB-4 above 2.67: high risk — referral to a hepatologist or gastroenterologist.

Liver elastography is the recommended next step for the indeterminate group. This is a non-invasive, 10–15 minute scan measuring liver stiffness (kPa) and liver fat content (CAP score in dB/m). It is available at clinics across Australia and at a growing number of centres does not require a GP referral.

Find a liver elastography clinic near you →

Based on Australian clinical guidelines and the emerging evidence on tirzepatide and liver health, the following monitoring schedule is reasonable for patients starting Mounjaro:

Before starting: Full liver function panel (ALT, AST, GGT, ALP, bilirubin, albumin) and platelets. Calculate FIB-4. If indeterminate or elevated, liver elastography before starting.

At 3 months: Repeat ALT and AST. Assess for transient elevation pattern versus persistent unexplained elevation.

At 12 months: Repeat FIB-4. If previously indeterminate, consider repeat elastography to assess whether fibrosis has improved.

Ongoing: Annual liver function panel while continuing Mounjaro.